UBS Group
ALXN

UBS Group’s Alexion Pharmaceuticals ALXN Stock Holding History

UBS Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,000
Closed -$1.08M – 8653
2019
Q4 		$1.08M Sell
10,000
-25,800
-72% -$2.76M ﹤0.01% 4136
2019
Q3 		$3.51M Buy
+35,800
New +$4.04M ﹤0.01% 2724
2019
Q1 		– Sell
-36,900
Closed -$3.59M – 8392
2018
Q4 		$3.59M Buy
+36,900
New +$4.36M ﹤0.01% 2470
2018
Q3 		– Sell
-166,400
Closed -$20.7M – 8413
2018
Q2 		$20.7M Sell
166,400
-233,200
-58% -$27.3M 0.01% 1148
2018
Q1 		$44.5M Buy
399,600
+212,800
+114% +$25.4M 0.02% 692
2017
Q4 		$22.3M Buy
186,800
+16,800
+10% +$2.05M 0.01% 1126
2017
Q3 		$23.8M Buy
+170,000
New +$23.1M 0.01% 1005
2017
Q2 		– Sell
-175,800
Closed -$21.3M – 8131
2017
Q1 		$21.3M Buy
175,800
+166,987
+1,895% +$21.5M 0.01% 998
2016
Q4 		$1.08M Sell
8,813
-65,287
-88% -$7.99M ﹤0.01% 3485
2016
Q3 		$9.08M Buy
74,100
+29,900
+68% +$3.85M 0.01% 1500
2016
Q2 		$5.16M Sell
44,200
-2,613
-6% -$371K ﹤0.01% 1925
2016
Q1 		$6.52M Buy
46,813
+36,513
+354% +$5.36M ﹤0.01% 1645
2015
Q4 		$1.97M Hold
10,300
– – ﹤0.01% 2807
2015
Q3 		$1.61M Hold
10,300
– – ﹤0.01% 2935
2015
Q2 		$1.86M Sell
10,300
-16,100
-61% -$2.78M ﹤0.01% 3047
2015
Q1 		$4.58M Buy
26,400
+9,000
+52% +$1.63M ﹤0.01% 2151
2014
Q4 		$3.22M Buy
+17,400
New +$3.22M ﹤0.01% 2457

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

UBS Group's ALXN Position: Q3 2021 in Review

UBS Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 451,615 shares — an estimated $83M sold.

UBS Group first reported a position in ALXN in Q4 2014 and held it in 27 quarters. The position peaked at $144M in Q4 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • UBS Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • UBS Group sold 451,615 Alexion Pharmaceuticals shares in Q3 2021, an estimated $83M.
  • UBS Group first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 27 quarters.
  • UBS Group's Alexion Pharmaceuticals position peaked at $144M in Q4 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on UBS Group's 13F filing for Q3 2021, filed 15 Nov 2021.